Organon reported second quarter 2025 total revenue of $1.594 billion, a decrease of 1% on both an as-reported and ex-FX basis compared to the second quarter of 2024. The company updated its full year 2025 revenue guidance to a range of $6.275 billion to $6.375 billion, an increase from previous guidance, with an expected nominal revenue growth of (2.0%) to (0.4%).
Women’s Health revenue increased 2% ex-FX, driven by a 15% ex-FX growth in the fertility business, partially offset by a 1% ex-FX decline in Nexplanon sales due to constrained federal and state subsidized program funding in the U.S. Biosimilars revenue increased 6% ex-FX, primarily from strong Hadlima performance. Established Brands revenue declined 4% ex-FX, impacted by Atozet LOE, but partially offset by contributions from Emgality and Vtama.
Net income for the quarter was $145 million, or $0.56 per diluted share, including a $46 million gain from early extinguishment of debt. Non-GAAP Adjusted net income was $261 million, or $1.00 per diluted share. Organon reaffirmed its full year 2025 Adjusted EBITDA margin guidance of 31.0%-32.0%. The company made principal repayments on long-term debt totaling $345 million during the quarter, including repurchasing and canceling $242 million of its 5.125% notes due in 2031.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.